SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (4032)12/21/2015 6:10:42 PM
From: mulanoon2007  Read Replies (1) of 4474
 
In December's Haematologica, MD Anderson show a little more love in their love-hate relationship with PON. Only 5 pts were enrolled in their "second line" phase 2 (before FDA safety concern) which evaluated PON following failure of IMA (n=3) or DAS (n=2). At median of 3 months, pts began receiving lower doses of PON (3 pts received 30 mg, 2 pts received 15 mg). After a median follow up of 22 months, cumulative best response for all patients was PCyR in one pt and MR4.5 in 4 pts. No thrombosis was reported.

Authors' state "Importantly, it is apparent from our results that patients can have sustained responses on lower doses of ponatinib, and the toxicity profile of ponatinib was manageable at these doses in our group."

haematologica.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News